Drug monitoring was conducted for rifapentine among people with HIV receiving dolutegravir containing antiretroviral therapy and latent tuberculosis treatment
Jeng-Hung Chen, Yi-Chun Lin, Cheng‐Pin Chen, Shu‐Hsing Cheng, Hui-Chun Hu, Hsiu-Wen Yeh, Hui-Ting Shieh, Chien‐Yu Cheng
Journal of Microbiology Immunology and Infection · 2024-11
Abstract
The proportion of trough plasma concentration of dolutegravir (DTG) above protein adjusted 90 % inhibition concentration (IC90) (0.064 mg/L) was 98.1 % across all visits during the twelve doses of once-weekly rifapentine and isoniazid (3HP) in people with HIV (PWH). Furthermore, the participants maintained a high rate of HIV viral suppression (98 %) within 6 months after completing 3HP.
MeSH terms
- Rifapentine
- Dolutegravir
- Medicine
- Latent tuberculosis
- Human immunodeficiency virus (HIV)
- Tuberculosis
- Isoniazid
- Antiretroviral therapy
- Drug
- Pharmacotherapy
- Pharmacology
- Internal medicine